Protagonist Therapeutics’ Insider Trading & Buy‑Back Strategy Shows Structured Growth & Investor Confidence
Protagonist Therapeutics’ CEO follows a 10(b)(5)(1) plan, buying and selling 143k shares while the company repurchases stock, showing disciplined liquidity and confidence in rare‑disease drug development.
- PROTAGONIST THERAPEUTICS INC
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read